NE-CHMIMO


NE-CHMIMO is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. NE-CHMIMO is the 1-cyclohexylmethyl analogue of the first-generation synthetic cannabinoid JWH-018. The corresponding cyclohexylmethyl derivative of JWH-081 had also been reported several months earlier.

Legal status

In the United States, all CB1 receptor agonists of the 3-indole class such as NE-CHMIMO are Schedule I [Controlled Substance]s.
NE-CHMIMO is a controlled substance in Japan as of November 2019.